Multiple Myeloma Pipeline Analysis Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape, and ASH 2023 Updates | Sanofi, Karyopharm, AbbVie, Takeda, Celgene, Bristol-Myers Squibb, Pfizer, BioLineRx, Celgene

Las Vega (Nevada), United States //- As per DelveInsight's assessment, globally, about 100+ key pharma and biotech companies are working on 130+ pipeline drugs in the Multiple Myeloma therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

"Multiple Myeloma Pipeline Insight, 2023" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Multiple Myeloma Therapeutics Market.

The report provides a detailed description of the Multiple Myeloma drugs, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any). The report also covers commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed stage. Additionally, it presents the ongoing developments in the therapeutics segment, including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product-related details.

Get a Detailed Overview of the Multiple Myeloma Clinical Trial Activities and Regulatory Developments in the domain @
https://www.delveinsight.com/report-store/multiple-myeloma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Multiple Myeloma Pipeline Analysis
The report provides insights into:
• The report provides detailed insights into the key companies that are developing Multiple Myeloma therapies.
• The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Multiple Myeloma treatment.
• It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• It navigates the emerging Multiple Myeloma drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement in the Multiple Myeloma treatment market.

Learn More about the Clinical and Commercial Development Activities in the Multiple Myeloma Therapeutics Domain @
https://www.delveinsight.com/report-store/multiple-myeloma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Multiple Myeloma Therapeutics Analysis
Treatment for multiple myeloma usually includes anti-myeloma medicines to destroy the myeloma cells or control cancer when it comes back (relapses) and medicines and procedures to prevent and treat problems caused by myeloma - such as bone pain, fractures, and anemia. The main treatment options include stem cell transplant, chemotherapy, targeted therapy, corticosteroids, proteasome inhibitors, immunomodulators, monoclonal antibodies, surgery, and radiation therapy. Also, the survival of patients with myeloma has also improved due to the development and approval of new treatments. Multiple Myeloma treatment strategies have also evolved with the emergence of new therapies with a novel mechanism of action and also with more complex combination regimens being used, such as quadruplets, triplets, and doublets.

To further improve the treatment outlook, there are approx. 100+ key companies developing therapies for Multiple myeloma. Currently, Janssen Pharmaceuticals is leading the therapeutics market with its Multiple myeloma drug candidates in the most advanced stage of clinical development.

Multiple Myeloma market is expected to grow in the upcoming years, owing to the rise in incident cases of Multiple Myeloma, high adoption of newer therapies, rich emerging pipeline, and expected increase in investment in R&D activities. Some factors such as toxicities, the burden of long-term therapy, differences in clinical care, and practice patterns between treatment centers, as well as access to and cost of therapy in real-world settings may also play a role in the observed gap between trial-based and real-world outcomes.

Key Developments in the Multiple Myeloma Market
• In August 2022, Janssen announced that the EC had granted CMA (conditional marketing authorization) to TECVAYLI (teclistamab) as monotherapy for the treatment of adult patients with R/R MM. Patients must have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody, and have demonstrated disease progression on the last therapy. This milestone marks the first approval worldwide for teclistamab, a first-in-class bispecific antibody that redirects CD3-positive T-cells to B-cell maturation antigen (BCMA)-expressing myeloma cells to induce the killing of tumor cells.
• In October 2022, the US FDA granted accelerated approval to TECVAYLI (teclistamab), for adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.

Multiple Myeloma Companies in the Therapeutics Market Include:
Sanofi, Karyopharm Therapeutics, AbbVie, Takeda Pharmaceutical, Celgene, Bristol-Myers Squibb, RAPA Therapeutics, Pfizer, Array Biopharma, Cellectar Biosciences, BioLineRx, Celgene, Aduro Biotech, ExCellThera, Janssen Pharmaceutical, Precision BioSciences, Takeda, Glenmark (Ichnos Sciences SA), Poseida Therapeutics, Molecular Partners AG, Chipscreen Biosciences, AbbVie/Genentech (Roche), Janssen Biotech, Nanjing Legend Biotech, Merck Sharp & Dohme Corp., Janssen, Regeneron Pharmaceuticals, Bristol-Myers Squibb, Cartesian Therapeutics, AstraZeneca, Abbvie (Pharmacyclics) and Johnson & Johnson, MorphoSys AG/I-Mab Biopharma and others.

Emerging and Marketed Multiple Myeloma Therapies Covered in the Report Include:
• Abecma (Idecabtagene vicleucel/bb2121/ ide-cel): Bristol-Myers Squibb/Bluebird bio
• Blenrep (Belantamab Mafodotin /GSK2857916): GlaxoSmithKline
• Ciltacabtagene Autoleucel (cilta-cel/ JNJ-4528/ JNJ-68284528/ LCAR-B38M): Janssen Biotech/Nanjing Legend Biotech
• Darzalex (Daratumumab): Janssen Biotech
• Elranatamab: Pfizer
• Felzartamab: Janssen Pharmaceutical
• Pepaxto (melflufen/ melphalan flufenamide): Oncopeptides AB
• REGN5458: Regeneron Pharmaceuticals
• Sarclisa (Isatuximab): Sanofi
• Venetoclax (ABT-199): AbbVie and Roche
• Xpovio (Selinexor): Karyopharm
And Many More

Get an in-depth Assessment of the Emerging Therapies and Multiple Myeloma Companies Actively Working in the Market @
https://www.delveinsight.com/sample-request/multiple-myeloma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

The Report Covers the Emerging Multiple Myeloma Therapies Under Different Phases of Clinical Development Like -
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued and inactive candidates

Route of Administration
Multiple myeloma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Intravenous
• Subcutaneous

Molecule Type
Products have been categorized under various Molecule types such as
• Small molecule
• Cell Therapy
• Peptides
• Polymer
• Small molecule
• Gene therapy

Request for Sample PDF to Understand More About the Multiple Myeloma Treatment Outlook and Future Perspectives @
https://www.delveinsight.com/sample-request/multiple-myeloma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Table of Content
1. Report Introduction
2. Executive Summary
3. Multiple Myeloma Current Treatment Patterns
4. Multiple Myeloma - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Multiple Myeloma Late-Stage Products (Phase-III)
7. Multiple Myeloma Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Multiple Myeloma Discontinued Products
13. Multiple Myeloma Product Profiles
14. Multiple Myeloma Companies
15. Multiple Myeloma Drugs
16. Dormant and Discontinued Products
17. Multiple Myeloma Unmet Needs
18. Multiple Myeloma Future Perspectives
19. Multiple Myeloma Analyst Review
20. Appendix
21. Report Methodology

Get Detailed Insights About the Reports Offerings @
https://www.delveinsight.com/sample-request/multiple-myeloma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Contact Info:
Shruti Thakur
Manager - Marketing & International Branding
Email: info@delveinsight.com

428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.